HighGravityData
Companies / Amgen / Filing

Amgen — Apr 30, 2026 release

Fiscal 2026 first-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0000318154-26-000054
Open on SEC.gov ↗
Showing in the filing
GAAP tax rate
“14.5 % — 16.0 %”
Period
FY2026
Measure
Company-defined measure
Source
Guidance table
All guidance in this release · 7
Total revenues for FY2026
“$37.1 billion to $38.5 billion”
Capital expenditures for FY2026
“approximately $2.6 billion”
Share repurchases for FY2026
“not to exceed $3.0 billion”
GAAP diluted EPS for FY2026
“$ 15.62 — $ 17.10”
Non-GAAP diluted EPS for FY2026
“$ 21.70 — $ 23.10”
GAAP tax rate for FY2026
“14.5 % — 16.0 %”
Non-GAAP tax rate for FY2026
“15.0 % — 16.5 %”
Exhibit 99.1 · the passage around this item
… earlier in the release
Our GAAP diluted EPS guidance does not include the effect of GAAP adjustments triggered by events that may occur subsequent to this press release such as acquisitions, asset impairments, litigation, changes in fair value of our contingent consideration obligations and changes in fair value of our equity investments. Reconciliation of GAAP Tax Rate Guidance to Non-GAAP Tax Rate Guidance for the Year Ending December 31, 2026 (Unaudited) GAAP tax rate guidance 14.5  % — 16.0  % Tax rate of known adjustments discussed above 0.5 % Non-GAAP tax rate guidance 15.0  % — 16.5  %
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.